# **DQA cases 2022**

#### DQA search audit Q3-2022 (summary)

- Weighted, arithmetic compliance rate of 82,8% for audits closed during the 12-months period from Q4/21 to Q3 2022
  - Confidence interval +2.5%/-2.5%
  - 909 files audited (including 19 files under the "old" search audit scheme, all compliant)
- Main finding (AC5 = invalid objection) is related to an incorrect assessment of novelty and inventive step in the written opinion, both in the independent and the dependent claims

2

Agreement rate auditors-examiners, 12-months: 98,8%

#### DQA search audit: Percentage of compliant files



DQA search audit: Compliance in DG1

# Categories

- AC1: highly relevant prior art missing
- AC2: Prior art fall-back embodiment
- AC3: Major objection missing
- AC4: Cited prior art more relevant than indicated
- AC5: Invalid objection
- AC6: Incorrect suggestion
- AC7: Wrong claims searched

#### Percentage of a files with a particular deficiency



#### Distribution of noncompliances according to legal basis



#### Dialogue between DG1 and DQA (Q4-2021 – Q3-2022)



European	Patent	Office	
----------	--------	--------	--

9

#### DQA grant audit Q3-2022 (summary)

- Midpoint of all closed audits now 75.3% arithmetically (compare midpoint Q3-2021 76.5%), confidence interval of +3.0/-3.0% means overall stable outcome, although below KPI
- Agreement rate with divisions over 12 months at 95.5% (down from 96.1% (Q3-2021) in the preceding reporting period)
- Disagreement with divisions on 35 cases (out of 785 audited files 12 months)
- Agreement rate with divisions in Q3-2022 at 97.1%

#### DQA grant audit: Percentage of compliant files in DG1



#### DQA grant audit: Findings in Q4-2021 to Q3-2022



#### DQA grant audit: Total agreement DQA-DG1 examining divisions (files; 12 months rolling)



### DQA grant audit: Maintaining a high agreement rate through dialogue (Q4-2021 – Q3-2022)



÷.

- Agreement rate DQA-EDs remaining stable at a high level
- Agreement rate by DG1 IRPs decreasing

## Results

- What was found for our sector?
  - Article 123(2) issues
  - Article 84 issues
  - Novelty objections missed
- No real trends
  - Most easily avoidable
- Why?
  - Not enough time spent or wrongly spent?
  - New ways of working

### **<u>Key messages</u>** - How to <u>stop</u> the '*easily avoidable*' non-compliances?

- 1) 8 eyes principle (1<sup>st</sup>, 2<sup>nd</sup>, CH, TM) with clear responsibilities to be taken <u>seriously</u>
- 2) really 'read' the claims through (also CH & TM!) and <u>understand</u> it with the mind of a technically/legally skilled person -> Art. 54, 56, 83, 84
- incomplete/suspicious Votum to be returned to / to be discussed with 1<sup>st</sup> (task of 2<sup>nd</sup>, CH, TM)
- 4) 1<sup>st</sup>/CH/TM: retrace amended features in original version (e.g. 123-check, JViewer- or ANSERA-highlights) -> Art. 123(2) and Art. 76(1)
  What, where and why
- 5) Be careful with Art. 84 objections [] can lead to Art. 123(2) problems

#### Back to Basics Examining Division: all members contribute positively to quality

With thanks to Andrea Bork (TM/1010

- First examiner: Propose decision
- Perform top-up search
- If helpful, discuss proposal with chairperson in advance
- Explain why the requirements for grant are fulfilled
- Include in the votum all the information needed for the division to validate grant, without duplication of work
- Adaptation of the description
  by applicant or examiner



#### Back to Basics Examining Division: all members contribute positively to quality

With thanks to Andrea Bork (TM/1010,

### Second examiner: Formal checks

- Formal correctness of eDREX working copy
  - -page breaks, transitions
  - -typographical / linguistic correctness of examiner amendments (*adaptation of description etc.*)
  - -claim numbering/dependencies
- Correctness of Form 2035
  Does it match with eDREX? etc.



Back to Basics Examining Division: all members contribute positively to quality

### **Chairperson:** Final review

- Read the claims
  - -Are they **clear**, plausible?
- Read the votum
  - -Prior art cited, novelty OK?
  - -Explanation of <u>why</u> it's inventive?
  - -Amendments identified and precise basis indicated?
  - -Intermediate generalisation identified and justified?
- Validate decision



